Joerg Zimmerman, director of process development and implementation at Vetter discusses the need to think carefully about the commercialization efforts that must be applied to a compound under development. Providing real world examples, Zimmerman runs through the technical challenges that biotech companies commonly face in drug development and offers some sound advice to facilitate the process. Zimmerman also talks on the regulatory focus on considering biological formulations in prefilled syringes as combination products and the need to establish compatibility at an early stage in development. Posted Feb. 2012.
